Pierre-Louis Toutain (Didier Concordet, P L Toutain, P-L Toutain)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 32

Top Topics

Escherichia Coli

Antimicrobial Resistance

Chronic Kidney Disease

Top Venues

Journal of veterinary pharmacology and therapeutics

Clinical pharmacokinetics

Equine veterinary journal

Drug testing and analysis

This page only lists publications with an associated author ORCID identifier.

Publications

Pierre-Louis Toutain
Why the racing industry and equestrian disciplines need to implement population pharmacokinetics: To learn, explain, summarize, harmonize, and individualize. Drug testing and analysis (2024)
Felipe Ramon Portugal, Marlène Z Lacroix, Béatrice B Roques, Véronique Gayrard, Pierre-Louis Toutain, Alain Bousquet-Mélou
Doxycycline serum protein binding in pigs reveals a relatively high free fraction. Journal of veterinary pharmacology and therapeutics (2023)
Felipe Ramon Portugal, Marlène Z Lacroix, Béatrice B Roques, Véronique Gayrard, Pierre-Louis Toutain, Alain Bousquet-Mélou
Doxycycline serum protein binding in pigs reveals a relatively high free fraction. Journal of veterinary pharmacology and therapeutics 46 (2) (2023)
Pierre-Louis Toutain, Peggy Gandia, Ludovic Pelligand, Aude A Ferran, Peter Lees, Alain Bousquet-Mélou, Didier Concordet
Biased computation of probability of target attainment for antimicrobial drugs. CPT: pharmacometrics & systems pharmacology (2023)
Felipe Ramon Portugal, Marlène Z Lacroix, Béatrice B Roques, Véronique Gayrard, Pierre-Louis Toutain, Alain Bousquet-Mélou
Doxycycline serum protein binding in pigs reveals a relatively high free fraction. Journal of veterinary pharmacology and therapeutics 46 (2) (2023)
Ina Schenk, Diane Broussou, Béatrice B Roques, Henrike Lagershausen, Marc Machnik, Helma Röttgen, Pierre-Louis Toutain, Mario Thevis
Control of a sulfadoxine/trimethoprim combination in the competition horse: Elimination, metabolism and detection following an intravenous administration. Drug testing and analysis (2023)
Peter Lees, Pierre-Louis Toutain, Jonathan Elliott, Jerome M Giraudel, Ludovic Pelligand, Jonathan N King
Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of veterinary pharmacology and therapeutics 45 (4) (2022)
Taisuke Kuroda, Yohei Minamijima, Hiroshi Mita, Norihisa Tamura, Kentaro Fukuda, Atsutoshi Kuwano, Pierre-Louis Toutain, Fumio Sato
Rational determination of cefazolin dosage regimen in horses based on pharmacokinetics/pharmacodynamics principles and Monte Carlo simulations. Journal of veterinary pharmacology and therapeutics (2022)
Andrew Mead, Pierre-Louis Toutain, Pascal Richez, Ludovic Pelligand
Quantitative Pharmacodynamic Characterization of Resistance versus Heteroresistance of Colistin in E. coli Using a Semimechanistic Modeling of Killing Curves. Antimicrobial agents and chemotherapy 66 (9) (2022)
Lena Ström, F Dalin, M Domberg, C Stenlund, U Bondesson, Mikael Hedeland, Pierre-Louis Toutain, Carl Ekstrand
Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. BMC veterinary research 17 (1) (2021)
Carmen Espinosa-Gongora, Lisbeth Rem Jessen, Oliver James Dyar, Alain Bousquet-Melou, Bruno González-Zorn, Céline Pulcini, Giovanni Re, Stefan Schwarz, Dorina Timofte, Pierre-Louis Toutain, Luca Guardabassi, null null, null null, null null
Towards a Better and Harmonized Education in Antimicrobial Stewardship in European Veterinary Curricula. Antibiotics (Basel, Switzerland) 10 (4) (2021)
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One? Clinical pharmacokinetics 59 (1) (2021)
Véronique Gayrard, Jessika Moreau, Nicole Picard-Hagen, Virginie Helies, Philippe Marchand, Jean-Philippe Antignac, Pierre-Louis Toutain, Roger Leandri
Use of Mixture Dosing and Nonlinear Mixed Effect Modeling of Eight Environmental Contaminants in Rabbits to Improve Extrapolation Value of Toxicokinetic Data. Environmental health perspectives 129 (11) (2021)
Taisuke Kuroda, Yohei Minamijima, Motoi Nomura, Shozo Yamashita, Masayuki Yamada, Shunichi Nagata, Hiroshi Mita, Norihisa Tamura, Kentaro Fukuda, Atsutoshi Kuwano, Shun-Ichi Nagata, Pierre-Louis Toutain, Fumio Sato
Medication control of flunixin in racing horses: Possible detection times using Monte Carlo simulations. Equine veterinary journal (2021)
Ina Schenk, Marc Machnik, Diane Broussou, Astrid Meuly, Béatrice B Roques, Elodie Anne Lallemand, Michael Düe, Helma Röttgen, Henrike Lagershausen, Pierre-Louis Toutain, Mario Thevis
Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. Journal of veterinary pharmacology and therapeutics 44 (5) (2021)
Taisuke Kuroda, Yohei Minamijima, Hidekazu Niwa, Norihisa Tamura, Hiroshi Mita, Kentaro Fukuda, Masahiro Kaimachi, Yuto Suzuki, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto, Pierre-Louis Toutain, Alain Bousquet-Melou, Yoshinori Kasashima
Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses. Equine veterinary journal 53 (6) (2021)
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?" Clinical pharmacokinetics 58 (7) (2020)
Peter Lees, Ludovic Pelligand, Etienne Giraud, Pierre-Louis Toutain
A history of antimicrobial drugs in animals: Evolution and revolution. Journal of veterinary pharmacology and therapeutics 44 (2) (2020)
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?" Clinical pharmacokinetics 58 (7) (2020)
D Concordet, P Gandia, J L Montastruc, A Bousquet-Mélou, P Lees, A A Ferran, Pierre-Louis Toutain
Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?" Clinical pharmacokinetics 59 (2) (2020)
Pierre-Louis Toutain, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?" Clinical pharmacokinetics 58 (7) (2020)
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Authors' Reply to Nicolas: "Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?" Clinical pharmacokinetics 59 (2) (2020)
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients? Clinical pharmacokinetics 58 (7) (2020)
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?" Clinical pharmacokinetics 58 (7) (2020)
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?" Clinical pharmacokinetics 58 (10) (2020)
Amir Atabak Ronaghinia, Nanett Kvist Nikolaisen, Stine Green Hansen, Helle Harding Poulsen, Henrik Lauritz Frandsen, Tina Struve, Pierre-Louis Toutain, Peter Damborg
Validating an empiric sulfadiazine-trimethoprim dosage regimen for treatment of Escherichia coli and Staphylococcus delphini infections in mink (Neovison vison). Journal of veterinary pharmacology and therapeutics 44 (1) (2020)
Pierre-Louis Toutain, Ludovic Pelligand, Peter Lees, Alain Bousquet-Mélou, Aude A Ferran, John D Turnidge
The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal. Journal of veterinary pharmacology and therapeutics 44 (2) (2020)
Alain Bousquet-Mélou, Marc Schneider, Farid El Garch, Diane C Broussou, Aude A Ferran, Elodie Anne Lallemand, Cyrielle Triboulloy, Peter Damborg, Pierre-Louis Toutain
Determination of the pharmacokinetic-pharmacodynamic cut-off values of marbofloxacin in horses to support the establishment of a clinical breakpoint for antimicrobial susceptibility testing. Equine veterinary journal 53 (5) (2020)
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A Ferran, Pierre-Louis Toutain
Authors' Reply to Yu et al.: "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?" Clinical pharmacokinetics 59 (2) (2020)
Andrew Mead, Peter Lees, John Mitchell, Andrew Rycroft, Joseph F Standing, Pierre-Louis Toutain, Ludovic Pelligand
Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media. Journal of veterinary pharmacology and therapeutics 42 (1) (2018)
C Bon, Pierre-Louis Toutain, D Concordet, Ronette Gehring, T Martin-Jimenez, J Smith, L Pelligand, Marilyn N Martinez, T Whittem, J E Riviere, Jonathan P Mochel
Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics. Journal of veterinary pharmacology and therapeutics 41 (2) (2017)
P Lees, T Potter, L Pelligand, Pierre-Louis Toutain
Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. Journal of veterinary pharmacology and therapeutics 41 (1) (2017)